The Journal of Practical Medicine ›› 2021, Vol. 37 ›› Issue (8): 1060-1067.doi: 10.3969/j.issn.1006⁃5725.2021.08.019

• Drugs and Clinic Practice • Previous Articles     Next Articles

Clinical efficacy of montelukast in patients with elevated serum LTC4 and FeNO ⁃ positive cough variant asthma

DI Jinna,SUI Liyun,ZHANG Li,LIU Jingyu.
  

  1. Department of Respiratory,Jinzhou Medical University Third Hospital,Jinzhou 121001,China

  • Online:2021-04-25 Published:2021-04-25
  • Contact: ZHANG Li E⁃mail:zhangli80809@126.com

Abstract:

Objective To explore the clinical efficacy of montelukast in the treatment of patients with elevated serum LTC4 and FeNO⁃positive cough variant asthma as well as its prognosis. Methods A total of 120 patients with cough variant asthma(CVA)were selected from the outpatient department of the respiratory department of our hospital and divided into groups A(increased serum LTC4,FeNO negative group),B(increased serum LTC4 FeNO positive group),C(low serum LTC4,FeNO positive group),and D(low serum LTC4,FeNO negative group),30 cases in each group. Another 30 healthy people were selected as the control group. All groups A,B,C and D received oral treatment of 10 mg montelukast once a night. After 1 month and 3 months of treatment,the efficacy of severe cough symptom score,LTC4,PEF and FeNO levels were evaluated respectively,and the patients were followed up for 3 months after the treatment. Follow ⁃ up visits were conducted for 3 months after the end of treatment. Results In group A,the cough symptoms were relieved after 1 month and 3 months of treatment,and the serum LTC4 level and PEF mutation rate were significantly reduced(P < 0.05). The cough symptoms in group B were relieved after 1 month and 3 months of treatment,and the serum LTC4 level,FeNO level,and PEF mutation rate were all reduced,the difference was statistically significant(P < 0.05);there was no statistical difference in the efficacy between the two groups(P > 0.05). The cough symptoms of the subjects in group C were slightly relieved after 1 month of treatment,FeNO levels and the PEF variation rate was slightly reduced,without statistically signifi⁃ cant difference(P > 0.05). After 1 month of treatment,the cough symptoms in group D were slightly relieved and the PEF variation insignificantly reduced(P > 0.05). Conclusion Montelukast has a good clinical effect in the treatment of adult CVA patients with elevated serum LTC4,but it is poor clinically for treating adult CVA patients with low serum LTC4. During the effective treatment period of 3 months,the longer the treatment duration is,the better the effect.

Key words: